Pharmacotherapy with amiodarone 200 mg per day; Treatment with Amiodarone at a dose 100 mg per day; Treatment with Amiodarone at a dose 400 mg per day
Проводит Tomsk National Research Medical Center of the Russian Academy of Sciences
Страница компанииRandomized Study of Integrated Assessment of Amiodarone Effects Based on Clinical Evaluation and Plasma Concentration Control in Patients With Paroxysmal Atrial Fibrillation in Parallel Groups
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07487714/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: 18–80 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 80 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановое окончание — 08.2027.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 4 · невключение: 9
Критерии включения
- The patient must have a documented electrocardiogram (ECG) or 24-hour ECG monitoring for paroxysmal AF.
- Patient age >18 years.
- Signed informed consent for participation in the study.
- Indications for amiodarone.
Критерии невключения
- for the study
- Contraindications to the administration of amiodarone according to the drug's instructions for use
- Patients with coronary artery disease with confirmed ischemia based on stress tests and the need for revascularization based on coronary angiography and multispiral computed tomography coronary angiography.
- Patients with resistant arterial hypertension.
- Planned catheter treatment of atrial fibrillation during the follow up period or early within 3 months postoperative period for catheter treatment of atrial fibrillation.
- Thrombosis of the heart cavities.
- Concomitant therapy with psychotropic drugs, antiarrhythmics of class IA and III, antibiotics, antifungal drugs, antimalarial and antiprotozoal drugs, antitumor, antiemetic drugs and drugs affecting gastrointestinal motility, antihistamines;
- Patients incapacitated due to psychoneurological conditions;
- Pregnant women or women of childbearing age planning pregnancy during the study.
Источник: ClinicalTrials.gov, NCT07487714 · запись обновлена в реестре 23 марта 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 8
- Incidence of of patients with recurrent atrial fibrillation paroxysms (percentage) — 106 days
Цель исследования
Amiodarone is a highly effective drug for the treatment and prevention of arrhythmias. In the 1970s and 1980s, numerous experimental and clinical studies comprehensively examined the mechanisms of amiodarone's antiarrhythmic action, as well as its effectiveness in various types of arrhythmias. This explains why drug therapy is so widespread today. According to the CAMIAT study, which included 1,202 patients with ventricular extrasystole who had suffered a myocardial infarction, amiodarone administration reduced the risk of arrhythmic death by 48.5%, and by 35% in the EMIAT study. In the GESICA study, amiodarone therapy was documented to reduce overall mortality by 45%, the incidence of sudden cardiac death by 54%, and mortality from progressive heart failure by 40%. In Russia, amiodarone is prescribed as a first-line drug for AF in 41% of cases with organic myocardial disease, in 52% as a second-line drug, and in 12.5% in the absence of organic heart damage. Moreover, the effectiveness of maintaining sinus rhythm in atrial fibrillation varies from 30 to 95.2%, which is a significant range when predicting the effectiveness of treatment. Attempts to assess amiodarone concentrations during therapy and to analyze the correlation with the achieved effects have been made repeatedly. While assessing amiodarone concentrations is generally considered inappropriate, based on the results of numerous studies, the use of monitoring is justified in certain clinical situations where the desired clinical effect or adverse events are absent. A detailed analysis of systemic reviews revealed significant shortcomings in the formation of such judgments. The groups were heterogeneous, small in number, and included, among other things, individual clinical situations and different routes of drug administration. A literature review did not reveal any data on the analysis of the concentration of amiodarone and desethylamiodarone as an anti-relapse therapy for atrial fibrillation when used consistently in doses acceptable by clinical guidelines with the possibility of titration under laboratory monitoring.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07487714 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, набор участников, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.